Meeting
2022 ASCO Annual Meeting
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.
Authors
Morten Nielsen
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark, Herlev, Denmark
Tine Monberg , Benedetta Albieri , Vibeke Sundvold , Oystein Rekdal , Niels Junker , Inge Marie Svane , Morten Nielsen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03725605
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11567)
DOI
10.1200/JCO.2022.40.16_suppl.11567
Abstract #
11567
Poster Bd #
471
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy.
First Author: Arjun Khunger
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.
First Author: Yongwoo David Seo
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Final report of a pilot trial combining ipilimumab and adoptive cell therapy.
First Author: John Mullinax
Poster
2015 ASCO Annual Meeting
T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo.
First Author: Courtney Regan